3BEMBARDIER C, GLADMAN DD, UROWITZ MB, et aL Derivation of the SLEDAI. A disease activity index for lupus patients: the committee on prognosis in SLE[J]. Arthritis Rheum, 1992, 35(2): 630-640.
4GUNTHER E, WALTER K, PETER S. Ligands working as receptors: reverse signaling by members of th TNF superfamily enhance the plasticity of the immune system [J]. Cytokine Grouth Factor Rev, 2004, 15(5): 353-366.
5SCHEINFELD N. A comprehensive review and evaluation of side effects of the tumor necrosis foctor alpha blockers etaneereept, infliximab and adalimumab [J]. J Dermatolog Treat, 2004, 15(5): 280-294.
6LIPSKY PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity [J]. Nat Immunol 2001, 2(9): 764-766.
7GRONDAL G, GUNNARSSON I, RONNELID J, et al. Cytokine production, serum levels and disease activity in systemie lupus erythematosus[J]. Clin Exp Rheumatoi, 2000, 18 (5): 565-570.
8FREYSDOTHR J, SIGFUSSON A. A flow eytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes [J]. Immunol Methods, 1991, 142(4): 45-52.
9SABRY A, ELBASYOUNI SR, SHEASHAA HA. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis [J]. Int Urol Nephrol, 2006, 38(3-4): 731-737.
10LOCKSLEY RM, KILLEEN N, LENARDO MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology[J]. Cell, 2001, 104(4): 487-501.
